About BioXcel Therapeutics, Inc. - Common Stock (BTAI)
Bioxcel Therapeutics is a biopharmaceutical company focused on innovative drug development to address unmet medical needs in the fields of neurology and psychiatry. Utilizing its proprietary artificial intelligence platform, the company aims to identify and advance novel therapeutics that can improve patient outcomes in challenging conditions such as agitation in Alzheimer's patients and cancer-related symptoms. Bioxcel's approach integrates data-driven decision-making and clinical research to bring forth potential treatments that enhance the quality of life for patients dealing with complex health issues. Read More
HARTFORD, Conn., March 23, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that the United States District Court for the District of Connecticut has approved the following announcement of a proposed class action settlement that would benefit purchasers of BioXcel Therapeutics, Inc. securities (NASDAQ: BTAI):
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders.
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
